Last updated: June 7, 2026
Sterile Water for Injection (SWFI) is sourced from large specialty sterile suppliers and generic sterile manufacturers that produce Water for Injection under CGMP in compliance with USP/EP requirements, typically supplied as 10 mL to 1,000 mL single-dose vials and large-volume containers, including common unit sizes used for reconstitution (e.g., hospital parenteral preparation).
Which companies supply Sterile Water for Injection (SWFI) in the US?
Major US and global suppliers generally fall into two buckets: (1) sterile injectable manufacturers producing SWFI under CGMP and (2) contract manufacturers that produce SWFI for labelers and distributors. In the US, market supply is highly fragmented at the SKU level (container size, closure, water-quality specification, packaging format).
Key US supplier profiles (manufacturer vs. labeler)
Common ways Sterile Water is marketed in the US include:
- Direct manufacturer label (branded generic style) sold as “Sterile Water for Injection, USP”
- Distributor or hospital-system label with outsourced CGMP manufacture
- Contract manufacturing for multiple NDC-labeled SKUs with different vial sizes and pack configurations
What NDC holders and labelers sell Sterile Water products?
Sterile Water for Injection is frequently sold as a generic (many NDCs, many labelers). NDC ownership may sit with:
- The CGMP manufacturer
- A repackager/distributor
- A marketing company that holds the NDC while a contract manufacturer supplies the product
What to look for when mapping the supplier chain
To identify the true manufacturing supplier, procurement teams typically match:
- NDC labeler and manufacturer (when available)
- Container configuration (single-dose vial, multi-pack, bulk container)
- Country of manufacture statements on carton labels
- DMF/plant associations for sterile water production sites (when disclosed in regulatory submissions)
How do Sterile Water suppliers qualify under USP <645> and CGMP?
Sterile Water used for injection is governed by pharmacopeial quality requirements and sterile manufacturing controls. Qualification typically focuses on:
- Microbial control and endotoxin limits consistent with pharmacopeial acceptance
- Water-system validation for purified water and WFI generation (often via distillation or reverse osmosis plus polishing depending on site design)
- Sterilization assurance validation for final container closure integrity
- Aseptic processing or terminal steam sterilization depending on fill configuration and container scale
- Sterile filtration only where applicable (often not used for SWFI if terminal sterilization is used after filling; practices vary by site)
What matters most for procurement
- Container closure system integrity testing and leak risk control
- Batch record traceability for reconstitution workflow
- Sterility assurance level documentation (site-specific)
- Supply continuity risk due to a limited number of high-capacity sterile water lines
When does Sterile Water for Injection lose exclusivity or face generic competition?
Sterile Water for Injection is a mature, non-proprietary product in most jurisdictions and generally does not run on the same exclusivity framework as patented small-molecule injectables. Competition is driven by:
- Capacity, quality systems, and regulatory compliance
- NDC and listing coverage
- Contract relationships and distributor allocation during shortages
What drives price and availability
- Contract manufacturing slots and line scheduling
- Outages tied to sterility assurance and aseptic line downtime
- Component constraints (vials, closures, carton packs)
- Regulatory actions that can remove batches or entire sites from market
What formulations and container types do suppliers offer?
Sterile Water is typically standardized as:
- Water for injection meeting USP/EP criteria
- Filled in single-dose vials or larger-volume containers for hospital use
- Common vial sizes include 10 mL, 20 mL, 30 mL, 50 mL and bulk containers such as 100 mL, 250 mL, 500 mL, and 1,000 mL depending on market
Packaging that affects procurement
- Single-dose vs multi-dose packs
- Carton counts aligned to hospital reconstitution workflow
- Closure type (rubber stoppers, crimp caps) and compatibility with needle access
Which suppliers are best positioned to manage Sterile Water shortages?
The ability to sustain supply depends on:
- WFI generation capacity and redundancy at the water-system level
- Sterile fill capacity (number of lines, container sizes, and changeovers)
- QA release throughput
- Finished goods packaging flexibility (vials and bulk containers)
- Regulatory record stability (inspection outcomes and deviations history)
Procurement decisions usually prioritize suppliers with:
- Multiple plants or alternate fill sites
- Proven ability to ramp during demand surges
- Strong complaint and deviation management record
How does Sterile Water supply chain differ from API or sterile injectables?
Sterile Water is not an API with patent-backed chemistry. The dominant barriers are:
- Sterile manufacturing capability
- Quality system robustness
- WFI generation and validation engineering
- Regulatory compliance and lot release discipline
Typical bottlenecks
- Sterile fill line availability
- Container and closure supply
- QMS-driven batch hold and release capacity
- Inspections that trigger remediation cycles
Which regions supply Sterile Water for the US market?
Sterile Water for Injection is often produced in the US and also imported depending on:
- Pricing
- Capacity utilization
- Regulatory status of foreign sites
- Contract arrangements with labelers and distributors
What is the Orange Book status of Sterile Water products?
Sterile Water for Injection is typically not an Orange Book-drug monopoly since it is not generally a patented proprietary drug product. Competitive listings are usually driven by NDC coverage rather than patent estates.
What patent estate covers Sterile Water for Injection?
Sterile Water is generally not associated with broad, enforceable product patents the way do small-molecule injectables or complex biologics. IP, where present, is more often found in:
- Specific manufacturing processes, filtration/sterilization methods
- Container closure or packaging configurations
- Proprietary formulation for combination products (when SWFI is mixed with other actives)
Key Takeaways
- Sterile Water for Injection is a low-IP, high-compliance sterile product where supplier selection is driven by CGMP capability, sterile fill capacity, WFI generation validation, and lot release reliability.
- Market competition is NDC- and capacity-driven rather than patent-exclusivity-driven.
- Procurement screening should prioritize multi-line sterile capacity, validated WFI systems, redundant packaging supply, and stable regulatory performance.
FAQs
- How do I identify the actual manufacturer behind a specific Sterile Water for Injection NDC?
- What container sizes for Sterile Water are most commonly used for hospital reconstitution workflows?
- What CGMP and pharmacopeial standards govern Sterile Water for Injection release testing?
- What causes Sterile Water supply disruptions during demand surges?
- How can distributors manage allocation risk for Sterile Water during shortages?
References
- U.S. Pharmacopeia (USP). USP General Chapters <645> and related standards for water and sterile preparation requirements.
- FDA. Current Good Manufacturing Practice (CGMP) regulations for drugs; sterile drug product guidance and inspectional frameworks.
